Leticia De Mattos-Arruda

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4785562/publications.pdf

Version: 2024-02-01

34 papers	2,876 citations	331670 21 h-index	434195 31 g-index
34 all docs	34 docs citations	34 times ranked	5586 citing authors

#	Article	IF	Citations
1	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncology, The, 2014, 15, 406-414.	10.7	703
2	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications, 2015, 6, 8839.	12.8	605
3	Clinical implications of intratumor heterogeneity: challenges and opportunities. Journal of Molecular Medicine, 2020, 98, 161-177.	3.9	241
4	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology, 2019, 134, 39-45.	4.4	200
5	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nature Reviews Clinical Oncology, 2013, 10, 377-389.	27.6	164
6	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget, 2015, 6, 37269-37280.	1.8	135
7	The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-4056.	7.0	119
8	Cellâ€free circulating tumour DNA as a liquid biopsy in breast cancer. Molecular Oncology, 2016, 10, 464-474.	4.6	101
9	The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. Cell Reports, 2019, 27, 2690-2708.e10.	6.4	95
10	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesisâ€generating study. Journal of Pathology, 2015, 237, 166-178.	4.5	53
11	Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. Molecular Oncology, 2014, 8, 1588-1602.	4.6	49
12	Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Future Oncology, 2011, 7, 1385-1397.	2.4	38
13	Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nature Reviews Clinical Oncology, 2016, 13, 566-579.	27.6	38
14	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. Molecular Oncology, 2014, 8, 150-158.	4.6	37
15	Brain metastasis: New opportunities to tackle therapeutic resistance. Molecular Oncology, 2014, 8, 1120-1131.	4.6	37
16	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. Histopathology, 2015, 67, 529-537.	2.9	37
17	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget, 2018, 9, 20617-20630.	1.8	36
18	Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer. Oncologist, 2012, 17, 631-644.	3.7	31

#	Article	IF	Citations
19	Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 279-289.	2.3	24
20	Pilot Studies for Personalized Cancer Medicine: Focusing on the Patient for Treatment Selection. Oncologist, 2013, 18, 1180-1188.	3.7	22
21	Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. Advances in Therapy, 2013, 30, 645-658.	2.9	21
22	Breast cancer and HSP90 inhibitors: Is there a role beyond the HER2-positive subtype?. Breast, 2012, 21, 604-607.	2.2	20
23	New emerging targets in cancer immunotherapy: the role of neoantigens. ESMO Open, 2019, 4, e000684.	4.5	20
24	Escaping Out of the Brain. Cancer Discovery, 2014, 4, 1259-1261.	9.4	12
25	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. European Journal of Cancer, 2021, 148, 134-145.	2.8	10
26	PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come. ESMO Open, 2020, 5, e000890.	4.5	8
27	Obesity and high neutrophil-to-lymphocyte ratio are prognostic factors in non-metastatic breast cancer patients. Brazilian Journal of Medical and Biological Research, 2021, 54, e11409.	1.5	8
28	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. Oncologist, 2022, 27, e561-e570.	3.7	5
29	PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2012, 30, 509-509.	1.6	3
30	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. Npj Breast Cancer, 2021, 7, 73.	5.2	2
31	Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.. Journal of Clinical Oncology, 2013, 31, 2561-2561.	1.6	2
32	News from ASCO 2018. Breast Care, 2018, 13, 298-302.	1.4	0
33	Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2012, 30, 566-566.	1.6	0
34	Analysis of the intratumoral heterogeneity of PIK3CA mutant alleles in breast cancer (BC): Implications for the luminal (LUM) phenotype.. Journal of Clinical Oncology, 2012, 30, 10511-10511.	1.6	0